Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but is not without risk. Neurokinin B signalling is increased in menopausal women, and has been implicated as an important mediator of hot flushes. METHODS: This phase 2, randomised, double-blind, placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes. Eligible participants were healthy women aged 40-62 years, having seven or more hot flushes in every 24 h of which some were reported as being severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not been taking any medication shown to improve menopausal flushes in the preceding 8 weeks. Participants received 4 weeks of MLE4901 (40 mg, orally, twice daily) and placebo (orally, twice daily) in random order separated by a 2 week washout period. Randomisation was completed by a central computer, and participants were allocated to treatment number in numerical order. The primary outcome was the total number of hot flushes during the final week of both treatment periods. Analyses were by intention to treat and per protocol using generalised linear mixed models and standard crossover analysis. All analyses were prespecified in the study protocol. The trial is registered at ClinicalTrials.gov, number NCT02668185. FINDINGS: 68 women were screened between Feb 3 and Oct 10, 2016, of which 37 were randomly assigned and included in an intention-to-treat analysis. 28 participants completed the trial and were included in a per-protocol analysis. MLE4901 significantly reduced the total weekly number of hot flushes by 45 percentage points (95% CI 22-67) compared with the placebo (intention-to-treat adjusted means: placebo 49·01 [95% CI 40·81-58·56] vs MLE4901 19·35 [15·99-23·42]; adjusted estimate of difference 29·66 [17·39-42·87], p<0·0001). Treatment was well tolerated. Three participants developed a transaminase rise (alanine aminotransferase 4·5-5·9 times the upper limit of normal) with a normal bilirubin 28 days after starting MLE4901, which normalised within 90 days. INTERPRETATION: Treatment with a neurokinin 3 receptor antagonist (MLE4901) could be practice changing as it safely and effectively relieves hot flush symptoms without the need for oestrogen exposure. Larger scale studies of longer duration are now indicated. FUNDING: UK Medical Research Council and National Institute for Health Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehman, M. N., Coolen, L. M., & Goodman, R. L. (2010) · Endocrinology · doi:10.1210/en.2010-0022 · Cited by 768
Rometo, A. M., Krajewski, S. J., Lou Voytko, M., & Rance, N. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0553 · Cited by 396
Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.003 · Cited by 380
The Hot Flash Related Daily Interference Scale
Carpenter, J. S. (2001) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00353-0 · Cited by 292
Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial
Freeman, E. W. (2011) · JAMA · doi:10.1001/jama.2010.2016 · Cited by 245
Motivations and Methods for Analyzing Pulsatile Hormone Secretion
Veldhuis, J. D., Keenan, D. M., & Pincus, S. M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0005 · Cited by 223
Self-citationAyers, B., Smith, M., Hellier, J., Mann, E., & Hunter, M. S. (2012) · Menopause · doi:10.1097/gme.0b013e31823fe835 · Cited by 207
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
The Menopause Transition: Signs, Symptoms, and Management Options
Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa764 · Cited by 631
The 2023 nonhormone therapy position statement of The North American Menopause Society
(2023) · Menopause · doi:10.1097/gme.0000000000002200 · Cited by 309
Lederman, S., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., English, M., Franklin, C., Lee, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00085-5 · Cited by 267
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Self-citation
Metadata
- Authors
- Prague, J. K., Roberts, R. E., Comninos, A. N., Clarke, S., Jayasena, C. N., Nash, Z., Doyle, C., Papadopoulou, D. A., Bloom, S. R., Mohideen, P., Panay, N., Hunter, M. S., Veldhuis, J. D., Webber, L. C., Huson, L., & Dhillo, W. S.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 389
- Issue
- 10081
- Pages
- 1809-1820
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2604269555
- Cited by
- 204
- References
- 7
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30823-1
- The paper
- Prague, J. K., Roberts, R. E., Comninos, A. N., Clarke, S., Jayasena, C. N., Nash, Z., Doyle, C., Papadopoulou, D. A., Bloom, S. R., Mohideen, P., Panay, N., Hunter, M. S., Veldhuis, J. D., Webber, L. C., Huson, L., & Dhillo, W. S. (2017). Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30823-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.